Unipath

May 17, 2006 04:00 ET

BinaxNOW® Malaria Provides Rapid Diagnosis Allowing Immediate, Targeted Treatment Of Malaria

LONDON, UNITED KINGDOM--(CCNMatthews - May 17, 2006) -

BinaxNOW® Malaria from Inverness Medical, a leading manufacturer of Rapid Immunodiagnostic Devices, is helping healthcare professionals around the world in the battle against malaria. Today, malaria is a preventable and treatable disease, yet it still kills over a million people a year, most of them young children living in Africa. In fact, a child somewhere dies of malaria every 30 seconds.

Despite the perception that malaria is an entirely African problem, 40% of the world's population is at risk of the disease. Almost every country in South and Central America is malaria endemic and incidences are rising in the Western Hemisphere. With the increase of long haul international leisure and business travel many people are at risk from returning home unaware they have contracted the disease.

According to the World Health Organisation (WHO), an estimated 30,000 international travelers fall ill with the disease annually. Symptoms of malaria sometimes do not occur until weeks or even months after exposure and prompt diagnosis and correct treatment can make the difference between life and death.

BinaxNOW® Malaria is a rapid field or laboratory test for the differential diagnosis of a malaria infection. The simple test provides results in just 15 minutes, allowing for accurate treatment and improved patient outcomes.

Utilising a patented card device, the BinaxNOW® Malaria Test follows a simple procedure where a whole blood finger-prick sample is added to a sample pad. After just 15 minutes the result can be read. This speed and simplicity allows diagnosis and targeted treatment to occur in the same patient visit, enabling healthcare workers to combat the threat of malaria as quickly as possible.

The Roll Back Malaria Strategy of WHO confirms that the diagnosis and treatment of malaria should start within 24 hours of the onset of symptoms to prevent progression to severe disease or death.

For further information email professionaldiagnostic@unipath.com or visit www.binax.com

Please access links below for photography:

http://www.ccnmatthews.com/docs/DZ598707.JPG

http://www.ccnmatthews.com/docs/10055279.JPG

http://www.ccnmatthews.com/docs/MalariaNewsRelease.doc

Notes to Editor:

Inverness Medical is a world leading provider of innovative diagnostic products for infectious diseases, women's health and chronic disease self-management.

The BinaxNOW® range of tests is designed for use by healthcare professionals only in hospitals, clinics, laboratories and other point of care settings.

- The BinaxNOW® Malaria Test is a rapid immunodiagnostic assay for the detection of circulating Plasmodium falciparum (P.f.) antigen, the most serious form, and an antigen that is common to all four species of malaria: Plasmodium falciparum (P.f.), Plasmodium vivax (P.v.), Plasmodium ovale (P.o.), and Plasmodium malariae (P.m.) in whole blood.

- Malaria is caused by Plasmodium falciparum, P. vivax, P. ovale, as well as P. malariae. The disease is transmitted through the bite of the Anopheles mosquito.

- According to World Health Organization estimates, 300-500 million people a year develop malaria. Countries in tropical Africa account for more than 90% of cases, with more than 6% of remaining cases occurring in India, Brazil, Sri Lanka, Afghanistan, Vietnam and Colombia.

- BinaxNOW® Tests are rapid immunochromatographic tests (ICT) that detect specific analyses in clinical specimens using a patented card device. These tests for bacteria, viruses and parasites are easy to use and even easier to interpret.

Contact Information

  • Unipath
    Media Enquiries
    professionaldiagnostic@unipath
    www.binax.com